^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | pamrevlumab (FG-3019) (Connective tissue growth factor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer
Published date:
03/01/2018
Excerpt:
FibroGen...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with locally advanced unresectable pancreatic cancer.
